Claritas Gaining Global Rights to R-107, Varied Nitric Oxide PAH Therapy
The agreement is expected to come into effect by May 15, pending regulatory approval.
Nitric oxide, a gas naturally found in the body, works as an antiviral, fighting off viruses. Claritas — previously known as Kalytera Therapeutics — initially acquired a license to advance R-107 as a potential treatment of SARS-CoV-2, the virus that causes COVID-19, and other viral infections.
Nitric oxide also works as a vasodilator: it relaxes and widens blood vessels, so that blood flows more easily through them with less pressure. In studies in an established rat model, R-107 showed an ability to treat PAH by dilating blood vessels and restoring blood pressure in the lungs, Claritas reported in a press release, with benefits persisting after treatment stopped.
Quick Approval for COVID Vaccines a Concern, Rare Disease Patients Say
More than half of the people with rare diseases and their caregivers, asked in a survey, were undecided or less than willing to be vaccinated for COVID-19 if a vaccine was approved under emergency use authorization instead of the routine process, the EveryLife Foundation for Rare Disease reports.
These findings highlight the need for a greater understanding of the U.S. Food and Drug Administration’s (FDA) emergency use authorization (EUA) process, as all current U.S. vaccines against this virus came via this pathway.